Search

Your search keyword '"E Fiscarelli"' showing total 67 results

Search Constraints

Start Over You searched for: Author "E Fiscarelli" Remove constraint Author: "E Fiscarelli"
67 results on '"E Fiscarelli"'

Search Results

1. 486: Virulence and antibiotic resistance of Achromobacter spp. isolates from chronic and occasional lung infection in cystic fibrosis patients

7. 72nd Congress of the Italian Society of Pediatrics

9. Microbial colonization of implanted silicone and polyurethane catheters

11. [Acute nonbacterial bronchopneumopathies in the 1st years of life. Diagnostic strategies and clinico-epidemiological peculiarities]

12. Serum Procalcitonin (PCT): a marker of acute infection in the neonatal period

14. Fatal disseminated Nocardia farcinica infection in a renal transplant recipient

15. The gut microbiota in cystic fibrosis: a complex community unveiled by meta-omics approaches'

16. Aryl Hydrocarbon Receptor Agonism Antagonizes the Hypoxia-driven Inflammation in Cystic Fibrosis.

17. The Fascinating History of Wound Healing Through Fine Arts.

18. In vitro Activity of Antivirulence Drugs Targeting the las or pqs Quorum Sensing Against Cystic Fibrosis Pseudomonas aeruginosa Isolates.

19. The positive outcome of educating HIV-infected children about beauty in an African village.

20. Untargeted Metagenomic Investigation of the Airway Microbiome of Cystic Fibrosis Patients with Moderate-Severe Lung Disease.

21. Essential oils against bacterial isolates from cystic fibrosis patients by means of antimicrobial and unsupervised machine learning approaches.

22. Clonal Diversity, Biofilm Formation, and Antimicrobial Resistance among Stenotrophomonas maltophilia Strains from Cystic Fibrosis and Non-Cystic Fibrosis Patients.

23. Evaluation of in vitro activity of ceftolozane-tazobactam compared to other antimicrobial agents against Pseudomonas aeruginosa isolates from cystic fibrosis patients.

24. Genetic Polymorphisms Affecting IDO1 or IDO2 Activity Differently Associate With Aspergillosis in Humans.

25. Prevalence, geographic risk factor, and development of a standardized protocol for fungal isolation in cystic fibrosis: Results from the international prospective study "MFIP".

26. Identification of FDA-Approved Drugs as Antivirulence Agents Targeting the pqs Quorum-Sensing System of Pseudomonas aeruginosa.

27. Organization of Patient Management and Fungal Epidemiology in Cystic Fibrosis.

28. Evolution of Stenotrophomonas maltophilia in Cystic Fibrosis Lung over Chronic Infection: A Genomic and Phenotypic Population Study.

29. A Different Microbiome Gene Repertoire in the Airways of Cystic Fibrosis Patients with Severe Lung Disease.

30. A mast cell-ILC2-Th9 pathway promotes lung inflammation in cystic fibrosis.

31. Stenotrophomonas maltophilia Phenotypic and Genotypic Diversity during a 10-year Colonization in the Lungs of a Cystic Fibrosis Patient.

32. Major discrepancies between what clinical trial registries record and paediatric randomised controlled trials publish.

33. IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosis.

34. Determination of ciprofloxacin and levofloxacin in human sputum collected from cystic fibrosis patients using microextraction by packed sorbent-high performance liquid chromatography photodiode array detector.

35. Cooperative pathogenicity in cystic fibrosis: Stenotrophomonas maltophilia modulates Pseudomonas aeruginosa virulence in mixed biofilm.

36. In vitro activity of colistin against biofilm by Pseudomonas aeruginosa is significantly improved under "cystic fibrosis-like" physicochemical conditions.

37. Characterization of Streptococcus pneumoniae clones from paediatric patients with cystic fibrosis.

38. Proteomics boosts translational and clinical microbiology.

39. Exposure to extremely low-frequency magnetic field affects biofilm formation by cystic fibrosis pathogens.

40. Evaluation of specific immune response in early P. aeruginosa infection in cystic fibrosis patients.

41. Hypoxia promotes danger-mediated inflammation via receptor for advanced glycation end products in cystic fibrosis.

42. Procalcitonin in detecting neonatal nosocomial sepsis.

43. Potential novel therapeutic strategies in cystic fibrosis: antimicrobial and anti-biofilm activity of natural and designed α-helical peptides against Staphylococcus aureus, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia.

44. MALDI-TOF MS proteomic phenotyping of filamentous and other fungi from clinical origin.

45. Haemophilus influenzae in children with cystic fibrosis: antimicrobial susceptibility, molecular epidemiology, distribution of adhesins and biofilm formation.

46. Molecular epidemiology of meticillin-resistant Staphylococcus aureus in Italian cystic fibrosis patients: a national overview.

47. Antibacterial and anti-biofilm effects of cathelicidin peptides against pathogens isolated from cystic fibrosis patients.

48. Pseudomonas aeruginosa infection in cystic fibrosis caused by an epidemic metallo-β-lactamase-producing clone with a heterogeneous carbapenem resistance phenotype.

49. Phenotypic and genotypic characterization of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis: genome diversity, biofilm formation, and virulence.

50. Analysis of heat-induced changes in protein expression of Stenotrophomonas maltophilia K279a reveals a role for GroEL in the host-temperature adaptation.

Catalog

Books, media, physical & digital resources